The Journal of Thoracic and Cardiovascular Surgery, Vol 72, 333-338, Copyright © 1976 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
Regional immunotherapy with intrapleural BCG for lung cancer
MF McKneally, C Maver, HW Kausel and RD Alley
A living vaccine, the bacille Calmette Guerin (BCG) strain of Mycobacterium
tuberculosis bovis, has been administered in a single postoperative
intrapleural dose as a controlled equivalent of postoperative empyema in 38
patients following pulmonary resection for lung cancer. This form of
regional immunotherapy is reasonably well tolerated if the vaccine is given
in a limited dose and if a follow-up course of isoniazid (INH) is
administered. In this report, the technical details of this new therapeutic
program are reviewed. The preliminary findings in a randomized prospective
clinical train of the technique indicate that patients with Stage I lung
cancer are significantly benefitted by the treatment. Patients with more
advanced disease are unimproved by this form of therapy.